Drugs / Lyophilized Plasma
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00968487 | Jun 2010 → Dec 2011 | — | HemCon Medical Technologies, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01541098 | Jan 2015 → Jan 2016 | — | HemCon Medical Technologies, Inc | Withdrawn | No outcome recorded |
| Phase 2 | NCT01547078 | Jan 2015 → Jan 2016 | liver disorder | HemCon Medical Technologies, Inc | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lyophilized Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00968487 ↗ |
| Action | Restore | “Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins.” NCT00968487 ↗ |
| Modality | Protein / enzyme biologic | “Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins.” NCT00968487 ↗ |
| Route | Other | “returned to the blood center for reconstitution and infusion into subjects” NCT00968487 ↗ |